Key Clinical Trials Assessing Darolutamide and Cognition
Darolutamide, a nonsteroidal androgen receptor inhibitor for non-metastatic castration-resistant prostate cancer, has been evaluated for cognitive effects in phase 3 trials, addressing concerns with earlier androgen deprivation therapies (ADTs) that crossed the blood-brain barrier.
The ARAMIS trial (NCT02231326), involving 1,509 patients, used the Montreal Cognitive Assessment (MoCA) at baseline, 12 months, and trial end. Darolutamide plus ADT showed no significant cognitive decline versus placebo plus ADT: mean MoCA change was -0.6 versus -0.4 points (p=0.5). Only 10.2% of darolutamide patients had MoCA decline ≥3 points at 12 months, compared to 9.0% on placebo.[1][2]
The ARASENS trial (NCT02799602), a phase 3 study of 1,306 metastatic hormone-sensitive prostate cancer patients, applied the Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog) scale. No meaningful differences emerged between darolutamide, docetaxel, and ADT versus placebo combinations; cognitive scores remained stable across arms.[3]
Preclinical Evidence on Brain Penetration and Mechanisms
Darolutamide's low blood-brain barrier penetration (CNS distribution ratio <0.1 in rodents) minimizes central nervous system exposure, unlike enzalutamide or apalutamide. In vitro and rat studies confirm it does not inhibit transporters like P-gp or BCRP at clinical doses, reducing risk of cognitive disruption via androgen receptor antagonism in the brain.[4][5]
Real-World and Post-Marketing Data
Interim analyses from the real-world PROOF registry (n>500) report cognitive adverse events in <2% of darolutamide users, aligning with trial rates. No new signals have prompted label changes for cognition.[6]
Patient-reported outcomes in ARAMIS extensions show sustained MoCA stability over 4+ years, with fall risk (a proxy for frailty/cognition) lower on darolutamide.[2]
Comparisons with Other Androgen Receptor Inhibitors
| Drug | Blood-Brain Barrier Crossing | Cognitive Decline Risk (Trials) |
|------|-------------------------------|---------------------------------|
| Darolutamide | Minimal (<0.1 ratio) | Low (MoCA stable; ARAMIS) [1] |
| Enzalutamide | High | Elevated (ENSEAR: 19% decline) [7] |
| Apalutamide | Moderate | Moderate (TITAN: minor MoCA drop) [8] |
Darolutamide consistently outperforms peers in cognitive preservation, linked to its chemical design.[4]
Ongoing Research and Limitations
Phase 4 studies like the DAROLUX trial (NCT05795106) monitor long-term cognition via MoCA and FACT-Cog in expanded populations. Gaps include limited data in elderly patients (>80) or those with baseline impairment; most trials excluded severe cognitive disorders.9
No dedicated neuroimaging or detailed neuropsychological batteries exist yet, but current evidence supports darolutamide's favorable profile.
Sources
[1]: ARAMIS trial (NEJM, 2019)
[2]: ARAMIS 4-year update (ESU 2023)
[3]: ARASENS (NEJM, 2022)
[4]: Pharmacokinetics review (Clin Pharmacokinet, 2019)
[5]: Bayer darolutamide data sheet
[6]: PROOF registry interim (ASCO GU 2024)
[7]: ENSEAR substudy (JCO, 2020)
[8]: TITAN cognitive analysis (Ann Oncol, 2021)